AllSight
Companies · AGEN · Biological Products, (No Diagnostic Substances)

AGENUS INC (AGEN)

AGENUS INC (AGEN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

AGENUS INC (AGEN) stock — financials & valuation

Key numbers for AGENUS INC (AGEN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 53/100 — a percentile rank of AGENUS INC’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.

Market cap$376.2M
P / E4.1×
P / S2.8×
EV / EBITDA9.5×
Gross margin99.5%
Operating margin27.3%
Net margin69.3%
Return on equity-46.1%
ROIC-18.6%
Revenue growth30.5%
Debt / equity-0.1×
Dividend yield0.0%

Is AGENUS INC overvalued? P/S looks fair vs its 5-year range.

Independent of the events above — derived from AGENUS INC’s own financial statements and shown as context, never as advice.

Aug 18, 2026Debt maturity extended
Agenus extends $24.75M debt to 2029, buying time at 13% with dilution
Aug 12, 2026CEO performance award
Agenus just made its CEO’s payday depend on an 8x stock surge
Aug 11, 2026New director
Board expands with new Rome-based attorney; no strategic change disclosed
Aug 6, 2026
Revenue narrowly beat estimates, but BATTMAN’s termination clouds the trial strategy
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact